ADAPY

SEC source: 0001104659-23-001088 · tm231655-1_4seq1.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,631

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price based on prices ranging from $1.65 to $1.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 92,941 ADSs and RSU-style options and other options covering an aggregate of 21,627,276 ordinary shares of the Issuer.

SEC source: 0001104659-23-001090 · tm231655-3_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,725

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price based on prices ranging from $1.65 to $1.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 60,257 ADSs and RSU-style options and other options covering an aggregate of 6,208,326 ordinary shares of the Issuer.

SEC source: 0001104659-23-001089 · tm231655-2_4seq1.xml · nonDerivative · entry 1

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,361

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price based on prices ranging from $1.65 to $1.73, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 22,975 ADSs and RSU-style options and other options covering an aggregate of 4,842,890 ordinary shares of the Issuer.

SEC source: 0001104659-22-097135 · tm2224996-1_4seq1.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,316

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on September 1, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is the sale price per ADS.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 89,625 ADSs and RSU-style options and other options covering an aggregate of 21,697,500 ordinary shares of the Issuer.

SEC source: 0001104659-22-084894 · tm2222258-2_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,829

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on August 1, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.7642 to $1.7808, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 55,428 ADSs and RSU-style options and other options covering an aggregate of 6,225,276 ordinary shares of the Issuer.

SEC source: 0001104659-22-084893 · tm2222258d1_4seq.xml · nonDerivative · entry 1

Piccina Cintia · CIK 0001907199 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,824

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 31, 2022 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.7642 to $1.7808, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 4,131,192 ordinary shares of the Issuer.

SEC source: 0001104659-22-077470 · tm2220260-8_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,104

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on July 2, 2018 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.67 to $1.69, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 52,324 ADSs and RSU-style options and other options covering an aggregate of 6,272,148 ordinary shares of the Issuer.

SEC source: 0001104659-22-076901 · tm2220260-7_4seq1.xml · derivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Ordinary Shares · 500,000 shares

Expires 2032-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-22-076898 · tm2220260-5_4seq1.xml · derivative · entry 1

Furey John · CIK 0001691218 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Ordinary Shares · 500,000 shares

Expires 2032-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-22-076895 · tm2220260-2_4seq1.xml · derivative · entry 1

Duncan Barbara Gayle · CIK 0001353128 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Ordinary Shares · 500,000 shares

Expires 2032-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-22-076894 · tm2220260-1_4seq1.xml · derivative · entry 1

MOTT DAVID M · CIK 0001219871 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000,439

Underlying: Ordinary Shares · 1,000,439 shares

Expires 2032-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount

SEC source: 0001104659-22-076897 · tm2220260-4_4seq1.xml · derivative · entry 1

Noble James · CIK 0001388000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 710,711

Underlying: Ordinary Shares · 710,711 shares

Expires 2032-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-22-076900 · tm2220260-6_4seq1.xml · derivative · entry 1

Alleva Lawrence M · CIK 0001553053 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 816,067

Underlying: Ordinary Shares · 816,067 shares

Expires 2032-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001209191-22-040313 · doc4.xml · derivative · entry 1

Behbahani Ali · CIK 0001613867 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 737,050

Underlying: Ordinary Shares · 737,050 shares

Expires 2032-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-22-076896 · tm2220260-3_4seq1.xml · derivative · entry 1

Sigal Charles Elliott · CIK 0001661908 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 737,050

Underlying: Ordinary Shares · 737,050 shares

Expires 2032-07-02

F1 · derivative.exercise_price: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-22-074926 · tm2219493-1_4seq1.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,290

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on June 27, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is the sale price per ADS.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 86,335 ADSs and RSU-style options and other options covering an aggregate of 21,732,612 ordinary shares of the Issuer.

SEC source: 0001104659-22-064008 · tm2216620-1_4seq1.xml · nonDerivative · entry 1

Wood Gavin · CIK 0001577539 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,000

F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by Gavin Wood. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc.

F2 · shares: The 39,000 ordinary shares reported in Column 4 are represented by 6,500 ADSs.

F3 · price: The price reported in Column 4 of $0.2904 per ordinary share is derived from the purchase price paid on May 20, 2022 of $1.7423 per ADS divided by six.

F4 · balance_after: The 96,000 ordinary shares reported in Column 5 include 57,000 ordinary shares represented by 9,500 ADSs owned by Mr. Wood prior to the purchase reported in Column 4. These shares are held in the form of ADSs by Mr. Wood.

SEC source: 0001104659-22-056007 · tm2214456-2_4seq1.xml · derivative · entry 2

Brewer Joanna Elizabeth · CIK 0001923834 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 223,512

Underlying: Ordinary Shares · 223,512 shares

Expires 2032-05-04

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.2513 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 55,878 Ordinary Shares on May 4, 2023 and will be exercisable as to the remainder in annual installments of 55,878 Ordinary Shares on the fourth of each May from May 4, 2024 through May 4, 2026.

SEC source: 0001104659-22-056007 · tm2214456-2_4seq1.xml · derivative · entry 1

Brewer Joanna Elizabeth · CIK 0001923834 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 333,792

Underlying: Ordinary Shares · 333,792 shares

Expires 2032-05-04

F1 · derivative.exercise_price: The exercise price was converted from GBP0.24 based on an exchange rate of U.S.$1.2513 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 83,448 Ordinary Shares on May 4, 2023 and will be exercisable as to the remainder in monthly installments of 6,954 Ordinary Shares on the fourth of each month from June 4, 2023 through May 4, 2026.

SEC source: 0001104659-22-009932 · tm221700-20_4seq1.xml · derivative · entry 3

Piccina Cintia · CIK 0001907199 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 335,184

Underlying: Ordinary Shares · 335,184 shares

Expires 2023-03-15

F6 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.34145 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-22-009932 · tm221700-20_4seq1.xml · derivative · entry 2

Piccina Cintia · CIK 0001907199 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 754,200

Underlying: Ordinary Shares · 754,200 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.34145 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 188,550 Ordinary Shares on January 31, 2023 and will be exercisable as to the remainder in annual installments of 188,550 Ordinary Shares on the thirty-first of each January from January 31, 2024 through January 31, 2026.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-22-009932 · tm221700-20_4seq1.xml · derivative · entry 1

Piccina Cintia · CIK 0001907199 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,376,992

Underlying: Ordinary Shares · 3,376,992 shares

Expires 2032-01-31

F1 · derivative.exercise_price: The exercise price was converted from GBP0.33 based on an exchange rate of U.S.$1.34145 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 844,248 Ordinary Shares on January 31, 2023 and will be exercisable as to the remainder in monthly installments of 70,350 Ordinary Shares on the last day of each month from February 28, 2023 through December 31, 2025 and 70,494 Ordinary Shares on January 31, 2026.

SEC source: 0001104659-22-005056 · tm221700-18_4seq1.xml · nonDerivative · entry 1

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,336

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.17 to $3.22, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 80,399 ADSs and RSU-style options and other options covering an aggregate of 9,503,664 ordinary shares of the Issuer.

SEC source: 0001104659-22-005053 · tm221700-15_4seq.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,312

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.17 to $3.22, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 74,023 ADSs and RSU-style options and other options covering an aggregate of 21,767,724 ordinary shares of the Issuer.

SEC source: 0001104659-22-005055 · tm221700-17_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,336

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.17 to $3.22, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 44,988 ADSs and RSU-style options and other options covering an aggregate of 6,302,610 ordinary shares of the Issuer.

SEC source: 0001104659-22-005054 · tm221700-16_4seq1.xml · nonDerivative · entry 1

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,529

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 16, 2020 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.17 to $3.22, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 19,446 ADSs and RSU-style options and other options covering an aggregate of 4,856,312 ordinary shares of the Issuer.

SEC source: 0001104659-22-004153 · tm221700-14_4seq1.xml · nonDerivative · entry 2

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,754

F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.53 to $3.55, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 70,302 ADSs and RSU-style options and other options covering an aggregate of 9,573,888 ordinary shares of the Issuer.

SEC source: 0001104659-22-004148 · tm221700-10_4seq1.xml · derivative · entry 2

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 314,256

Underlying: Ordinary Shares · 314,256 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the twelfth of each January from January 12, 2024 through January 12, 2026.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-22-004148 · tm221700-10_4seq1.xml · derivative · entry 1

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,407,072

Underlying: Ordinary Shares · 1,407,072 shares

Expires 2032-01-12

F1 · derivative.exercise_price: The exercise price was converted from GBP0.44 based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the twelfth of each month from February 12, 2023 through December 12, 2025 and 29,454 Ordinary Shares on January 12, 2026.

SEC source: 0001104659-22-004149 · tm221700-11_4seq.xml · nonDerivative · entry 2

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,356

F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.53 to $3.55, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 54,689 ADSs and RSU-style options and other options covering an aggregate of 21,908,172 ordinary shares of the Issuer.

SEC source: 0001104659-22-004147 · tm221700-5_4seq1.xml · derivative · entry 2

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,047,480

Underlying: Ordinary Shares · 1,047,480 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 261,870 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 261,870 Ordinary Shares on the twelfth of each January from January 12, 2024 through January 12, 2026.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-22-004147 · tm221700-5_4seq1.xml · derivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,690,224

Underlying: Ordinary Shares · 4,690,224 shares

Expires 2032-01-12

F1 · derivative.exercise_price: The exercise price was converted from GBP0.44 based on an exchange rate of $U.S. 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 1,172,556 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 97,710 Ordinary Shares on the twelfth of each month from February 12, 2023 through December 12, 2025 and 97,818 Ordinary Shares on January 12, 2026.

SEC source: 0001104659-22-004154 · tm221700-7_4seq1.xml · derivative · entry 2

Wood Gavin · CIK 0001577539 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 314,256

Underlying: Ordinary Shares · 314,256 shares

Expires 2032-01-12

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the twelfth of each January from January 12, 2024 through January 12, 2026.

SEC source: 0001104659-22-004154 · tm221700-7_4seq1.xml · derivative · entry 1

Wood Gavin · CIK 0001577539 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,407,072

Underlying: Ordinary Shares · 1,407,072 shares

Expires 2032-01-12

F1 · derivative.exercise_price: The exercise price was converted from GBP0.44 based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the twelfth of each month from February 12, 2023 through December 12, 2025 and 29,454 Ordinary Shares on January 12, 2026.

SEC source: 0001104659-22-004151 · tm221700-6_4seq1.xml · derivative · entry 2

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 471,360

Underlying: Ordinary Shares · 471,360 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 117,840 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 117,840 Ordinary Shares on the twelfth of each January from January 12, 2024 through January 12, 2026.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-22-004151 · tm221700-6_4seq1.xml · derivative · entry 1

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,110,608

Underlying: Ordinary Shares · 2,110,608 shares

Expires 2032-01-12

F1 · derivative.exercise_price: The exercise price was converted from GBP0.44 based on an exchange rate of $U.S. 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 527,652 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 43,968 Ordinary Shares on the twelfth of each month from February 12, 2023 through December 12, 2025 and 44,076 Ordinary Shares on January 12, 2026.

SEC source: 0001104659-22-004156 · tm221700-8_4seq1.xml · derivative · entry 2

TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 314,256

Underlying: Ordinary Shares · 314,256 shares

Expires 2032-01-12

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on January 12, 2024 and January 12, 2025, and 78,564 Ordinary Shares on January 12, 2026.

SEC source: 0001104659-22-004156 · tm221700-8_4seq1.xml · derivative · entry 1

TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,407,072

Underlying: Ordinary Shares · 1,407,072 shares

Expires 2032-01-12

F1 · derivative.exercise_price: The exercise price was converted from GBP0.44 based on an exchange rate of U.S. $1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the twelfth of each month from February 12, 2023 through December 12, 2025 and 29,454 Ordinary Shares on January 12, 2026.

SEC source: 0001104659-22-004157 · tm221700-9_4seq.xml · derivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 314,256

Underlying: Ordinary Shares · 314,256 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 78,564 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the twelfth of each January from January 12, 2024 through January 12, 2026.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-22-004157 · tm221700-9_4seq.xml · derivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,407,072

Underlying: Ordinary Shares · 1,407,072 shares

Expires 2032-01-12

F1 · derivative.exercise_price: The exercise price was converted from GBP0.44 based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 351,768 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the twelfth of each month from February 12, 2023 through December 12, 2025 and 29,454 Ordinary Shares on January 12, 2026.

SEC source: 0001104659-22-004152 · tm221700-13_4seq1.xml · nonDerivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,749

F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.53 to $3.55, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 36,896 ADSs and RSU-style options and other options covering an aggregate of 6,372,834 ordinary shares of the Issuer.

SEC source: 0001104659-22-004150 · tm221700-12_4seq1.xml · nonDerivative · entry 2

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,383

F4 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.53 to $3.55, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.

F6 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 11,720 ADSs and RSU-style options and other options covering an aggregate of 4,890,212 ordinary shares of the Issuer.

SEC source: 0001104659-22-004153 · tm221700-14_4seq1.xml · nonDerivative · entry 1

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,343

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.48 to $3.64, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 70,302 ADSs and RSU-style options and other options covering an aggregate of 9,573,888 ordinary shares of the Issuer.

SEC source: 0001104659-22-004149 · tm221700-11_4seq.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,978

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.48 to $3.64, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 54,689 ADSs and RSU-style options and other options covering an aggregate of 21,908,172 ordinary shares of the Issuer.

SEC source: 0001104659-22-004152 · tm221700-13_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,343

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. Each exercise of the portion of these RSU-style share options and each sale reported in this Form 4 was effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.48 to $3.64, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 36,896 ADSs and RSU-style options and other options covering an aggregate of 6,372,834 ordinary shares of the Issuer.

SEC source: 0001104659-22-004150 · tm221700-12_4seq1.xml · nonDerivative · entry 1

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,343

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 11, 2021, and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.48 to $3.64, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from each Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 11,720 ADSs and RSU-style options and other options covering an aggregate of 4,890,212 ordinary shares of the Issuer.

SEC source: 0001104659-22-001671 · tm221700-4_4seq1.xml · nonDerivative · entry 1

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,873

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price based on prices ranging from $4.04 to $4.10, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 64,429 ADSs and RSU-style options and other options covering an aggregate of 7,949,250 ordinary shares of the Issuer.

SEC source: 0001104659-22-001668 · tm221700-1_4seq1.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,172

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price based on prices ranging from $4.04 to $4.10, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 48,517 ADSs and RSU-style options and other options covering an aggregate of 16,390,920 ordinary shares of the Issuer.

SEC source: 0001104659-22-001670 · tm221700-3_4seq1.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,755

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price based on prices ranging from $4.04 to $4.10, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 35,141 ADSs and RSU-style options and other options covering an aggregate of 4,729,134 ordinary shares of the Issuer.

SEC source: 0001104659-22-001669 · tm221700-2_4seq1.xml · nonDerivative · entry 1

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,388

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which have vested. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price based on prices ranging from $4.04 to $4.10, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 10,332 ADSs and RSU-style options and other options covering an aggregate of 2,382,344 ordinary shares of the Issuer.